Health care

Kno2 Launches New MuleSoft Integration

Retrieved on: 
Thursday, April 4, 2024
Cloud, Communication, Organization, Growth, Health, SVP, Health care, MuleSoft, Electronic health record, API, ONC

BOISE, Idaho, April 04, 2024 (GLOBE NEWSWIRE) -- Kno2, today announced a new MuleSoft Certified Connector for Kno2, which is accessible in the MuleSoft Anypoint Exchange and will allow companies to simplify integration to Kno2 Connector - Mule 4.

Key Points: 
  • BOISE, Idaho, April 04, 2024 (GLOBE NEWSWIRE) -- Kno2, today announced a new MuleSoft Certified Connector for Kno2, which is accessible in the MuleSoft Anypoint Exchange and will allow companies to simplify integration to Kno2 Connector - Mule 4.
  • Customers can leverage pre-developed assets from MuleSoft’s Accelerator for Healthcare to quickly establish integrations between Health Cloud and Kno2.
  • With the Kno2 MuleSoft Connector , organizations can expedite growth, reduce time spent on repetitive tasks, and create efficient workflows and integrations.
  • MuleSoft customers can learn more about MuleSoft Certified Connector for Kno2 by visiting: https://www.mulesoft.com/exchange/com.mulesoft.connectors/mule4-Kno2-con...
    Salesforce, MuleSoft, Health Cloud and others are trademarks of Salesforce, inc.

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

Retrieved on: 
Thursday, April 4, 2024
Pre-exposure prophylaxis, Webcast, COVID-19, Patient, Health care, SARS-CoV-2, Vaccination, Safety, Immunodeficiency, FDA, Food, Vaccine

Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.

Key Points: 
  • Recipients should not be currently infected with or have had a known recent exposure to an individual infected with SARS-CoV-2.
  • With product now available, today we are providing initial PEMGARDA net product revenue guidance in the range of $150 million to $200 million for the full year 2024.
  • For additional information about PEMGARDA, please see the full product Fact Sheet for Healthcare Providers, including important safety information and boxed warning.
  • Those who plan on participating are advised to join 15 minutes prior to the start time.

Augmedix and SADA Forge Partnership to Scale Ambient Documentation and Structured Data Products to Health Systems Nationwide

Retrieved on: 
Thursday, April 4, 2024
Cloud, GCP, Google Cloud, Organization, Documentation, Partnership, Patient, SAN, Health care, Artificial intelligence, Architecture, Google Cloud Platform, Machine learning, Health, Nursing

The collaboration is focused on leveraging the companies’ combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products.

Key Points: 
  • The collaboration is focused on leveraging the companies’ combined technology expertise and expanding their reach to provide greater product and service value to health systems seeking high-quality ambient documentation and structured data products.
  • “Together, we can accelerate efforts to bring ambient medical documentation and data solutions to benefit more patients and clinicians.”
    SADA provides cloud, data, artificial intelligence, cybersecurity, and intelligent edge solutions and services.
  • "Augmedix's partnership with SADA will help bring ambient documentation to more healthcare organizations around the country," said Amy Waldron, global director of Healthcare Strategy & Solutions, Google Cloud.
  • This collaboration underscores our commitment to empowering organizations like Augmedix and SADA to drive meaningful change in the healthcare industry."

Healthcare Triangle Breaks New Ground in AI-Powered Patient Data Management with readabl.ai

Retrieved on: 
Wednesday, April 3, 2024
Automation, FHIR, Intelligence, Electronic health record, LLM, API, HCTI, Interim, Machine learning, Triangle, Health, Health care

This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the standards for enhanced care delivery.

Key Points: 
  • This collaboration establishes a revolutionary benchmark in the management and utilization of patient data, ultimately elevating the standards for enhanced care delivery.
  • By leveraging Healthcare Triangle’s expertise in artificial intelligence and machine learning, the system adeptly identifies and extracts vital data from documents, faxes, and narrative reports.
  • A hallmark of this collaboration is Healthcare Triangle’s development of an unparalleled AI model that actively learns from real-time healthcare data.
  • Key Achievements through this collaboration Include:
    Enhanced Patient Care: Improved patient data processing speed and accuracy significantly boosts the delivery of patient care.

Molecure has published its financial report for 2023 - the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025

Retrieved on: 
Wednesday, April 3, 2024
Medical device, Annual report, ARG1, Documentation, Biotechnology, Sarcoidosis, Partnership, Patient, Scientific Research Publishing, USP7, Ethics, SPO, Biomarker, Research, Health care, Conception, Cancer, Messenger, POC, PLN, Biology, Royal, MHRA, Polish, Clinical trial, Safety, MOC, Phase, ARG2, Food, FDA, SMART, CDA, Pharmaceutical industry

We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.

Key Points: 
  • We initiated clinical trials of our drug candidate, which was discovered and brought into clinical trials for cancer patients by Molecure.
  • In 2023, our focus was also on preparing for a Phase II clinical trial for OATD 01, Molecure's flagship clinical programme.
  • We are very pleased to report that the first patient has started dosing in a clinical trial at a clinical site in the UK.
  • The Company plans to obtain further grants for projects within the framework of the pipeline developed so far.

DIGITAL ALLY, INC ANNOUNCES 2023 OPERATING RESULTS

Retrieved on: 
Tuesday, April 2, 2024
Agreement, Social media, Health care, Sale, Business analyst, Closing, Note, Marketing, Moshing, Form, Heartland Stampede Music Festival, Prospectus, George M. Steinbrenner Field, Kustom, Plan, Country, News, Acquisition, Senior, Suite, Security, Brickell Avenue, Security agreement, Operating cost, EDT, Sub, The Borrowers, Finance Secretary (India), Traction, Music, ID, Patent, DGLY, Cryptocurrency

LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.

Key Points: 
  • LENEXA, Kansas, April 02, 2024 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (the “Company” or “our”), today announced its operating results for fiscal year 2023.
  • Operating losses for the year ended December 31, 2023 and 2022 were $22,240,553 and $29,733,258, respectively, a decrease of $7,492,705 (25%).
  • Operating loss as a percentage of revenues improved to 78% in 2023 from 80% in 2022.
  • The Company will host an investor conference call at 11:15 a.m. EDT on Tuesday, April 2, 2023, to discuss its 2023 financial results, corporate and individual subsidiary outlook, and previously announced corporate separation.

Verve Therapeutics Announces Updates on its PCSK9 Program

Retrieved on: 
Tuesday, April 2, 2024
LDLR, Cardiovascular disease, Gene editing, PCSK9, ALT, Patient, RNA, Health care, Health Canada, IND, N-Acetylgalactosamine, MHRA, Asialoglycoprotein receptor, Clinical trial, CTAS, Therapy, Bleeding, Safety, Moyamoya disease, DSMB, FDA, Liver, ASCVD, LNP, Medsafe, Hypercholesterolemia, Food, Pharmaceutical industry

BOSTON, April 02, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced updates from the Heart-1 Phase 1b clinical trial of VERVE-101 and clearance of its Clinical Trial Applications (CTAs) by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) and Health Canada for VERVE-102, with the Heart-2 Phase 1b clinical trial expected to initiate in the second quarter of this year.

Key Points: 
  • Six participants have been dosed at 0.45 mg/kg of VERVE-101, with a total of 13 participants dosed in the study.
  • Verve is conducting an investigation into the laboratory abnormalities and based on those results, expects to work with regulatory authorities to define a path forward for VERVE-101.
  • Verve is now prioritizing the development of VERVE-102 and the initiation of the Heart-2 clinical trial.
  • VERVE-102 uses the same base editor and guide RNA for PCSK9 but a different lipid nanoparticle (LNP) delivery system than VERVE-101.

INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in agilon health, inc. with Losses of $100,000 to Contact the Firm

Retrieved on: 
Tuesday, April 2, 2024
Certification, Patient, Ethics, Health care, Complaint, Suite, Security (finance)

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.

Key Points: 
  • We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.
  • The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney.
  • The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Luna Named Among 2024's Most Innovative Healthcare Companies by Fast Company

Retrieved on: 
Tuesday, April 2, 2024
Health, Risk, Patient, Health care, MSK, Uber, Artificial intelligence, Nursing

Recognized for its outstanding contributions to healthcare, Luna secured the #13 position in the Healthcare category, showcasing its commitment to revolutionizing patient care and physical therapy accessibility.

Key Points: 
  • Recognized for its outstanding contributions to healthcare, Luna secured the #13 position in the Healthcare category, showcasing its commitment to revolutionizing patient care and physical therapy accessibility.
  • Luna’s innovative model combines the best of personalized at-home care with the convenience of technology.
  • According to Fast Company , “Luna, since its founding in 2018, has been committed to helping patients with MSK conditions and post-operative patients improve their conditions via in-home physical therapy appointments.
  • Luna also launched a dedicated Artificial Intelligence (AI) division named Luna Labs to enhance patient care, organized under the company’s Co-Founder, Chief Technology Officer, and former Uber engineer Ryan Gaffney.

John Snow Labs Announces First-Ever Generative AI Lab, Empowering Domain Experts to Train, Tune, and Test AI Models Without Coding

Retrieved on: 
Tuesday, April 2, 2024
NLP, Health care, News, AI, Graphics processing unit, Internet access, Lawyer, Safety, API, Generative, Medical device

LEWES, Del., April 02, 2024 (GLOBE NEWSWIRE) -- John Snow Labs , the AI for healthcare company, today announced the release of its Generative AI Lab, a first-of-its-kind tool that enables healthcare domain experts to train, tune, test, and share models without coding or involving data scientists.

Key Points: 
  • LEWES, Del., April 02, 2024 (GLOBE NEWSWIRE) -- John Snow Labs , the AI for healthcare company, today announced the release of its Generative AI Lab, a first-of-its-kind tool that enables healthcare domain experts to train, tune, test, and share models without coding or involving data scientists.
  • The Generative AI Lab is the only no-code solution designed for the most commonly requested use cases since the emergence of large language models (LLMs).
  • While models handle the legwork, the Generative AI Lab not only augments decision-making abilities for domain experts, but empowers them to train better models as they go.
  • “We’ve been using the Generative AI Lab for over a year to extract information from safety data sheets with regulatory-grade accuracy,” said Vishnu Vettrivel, CEO, Wisecube AI .